Repligen Corp. 10-Q Summary: Quarter Ended September 30, 2002
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2002, and the six months ended on that date. Repligen Corporation operates in two primary areas: the commercial sale of specialty pharmaceutical products (Protein A for antibody purification and SecreFlo for diagnostic use) and the clinical development of therapeutic candidates for pediatric developmental disorders (autism, mitochondrial disease) and autoimmune disorders (ITP). The company recently relocated to a new corporate headquarters in Waltham, Massachusetts, in May 2002.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2002 | Six Months Ended Sep 30, 2002 |
|---|---|---|
| Product Sales | $1,687,490 | $3,306,932 |
| Gross Margin | $1,025,693 (61%) | $1,975,489 (60%) |
| Net Loss | $(1,082,648) | $(2,073,787) |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.08) |
| Cash and Cash Equivalents | $9,684,545 | $9,684,545 (Balance Sheet) |
| Total Cash, Equivalents & Marketable Securities | $19,642,751 (Current + Long-term) | |
| Working Capital | $15,812,498 |
Debt and Liquidity: The company has no long-term debt. Current liabilities include a $2,576,025 license fee payable (non-cash stock issuance) and standard operating payables. Liquidity is supported by approximately $19.6 million in cash and marketable securities. Management believes this is sufficient to fund operations for the next 24 months.
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 90% ($800,000) for the quarter and 107% ($1.7 million) for the six months compared to the prior year periods. This is driven by increased demand from value-added resellers and shipments to Amersham Pharmacia Biotech.
- Margin Expansion: Gross margin improved significantly from 37% to 61% (quarterly) and 43% to 60% (six-month) due to a favorable mix of Protein A product sales and operational efficiencies.
- Expense Increases: Selling, General, and Administrative (SG&A) expenses rose 48% ($329,000) for the quarter, attributed to increased staffing, litigation costs, and relocation expenses. Research and Development (R&D) expenses decreased 6% ($76,000) for the quarter due to lower clinical material costs.
- Investment Income: Investment and interest income declined 48% ($146,000) for the quarter due to lower interest rates and reduced average funds available for investment.
Outlook, Risks, and Unusual Items
Outlook and Guidance: Management anticipates significantly higher costs in fiscal 2003 due to expanded clinical trials for proprietary drug candidates (secretin for autism, uridine for mitochondrial disease, CTLA4-Ig for ITP) and the commercial launch of SecreFlo. No specific revenue guidance was provided, though the company expects to fund operations for the next 24 months with existing capital.
Unusual Items:
- SecreFlo Licensing: In connection with FDA approval of SecreFlo, the company recorded a $2,576,025 non-cash charge (value of stock issued to ChiRhoClin, Inc.) and paid a $1.25 million cash milestone. This amount is being amortized over seven years.
- Relocation: Capital expenditures of $943,000 were incurred for the new Waltham facility, which will increase annual rent by approximately $230,000.
Risks and Contingencies:
- Legal Proceedings: Repligen is involved in patent litigation with Pro-Neuron, Inc. regarding uridine rights (mitochondrial disease) and with Bristol-Myers Squibb regarding CTLA4-Ig inventorship. A trial against Bristol is scheduled for April 2003. Adverse outcomes could restrict commercialization rights.
- Customer Concentration: Two customers accounted for 39% and 36% of revenues in the quarter ended September 30, 2002.
- Regulatory Approval: Future success depends on FDA approvals for therapeutic candidates and maintaining the Orphan Drug status for SecreFlo.
Investor Verification Checklist
- Verify the status and potential financial impact of the pending patent litigation against Bristol-Myers Squibb and Pro-Neuron, Inc.
- Confirm the commercial uptake of SecreFlo following its October 2002 launch and the associated royalty obligations to ChiRhoClin.
- Monitor the progress of Phase 3 clinical trials for secretin in autism and the planned IND submissions for uridine.
- Assess the sustainability of the 60%+ gross margin as the product mix shifts and new products are introduced.
- Review the company's cash burn rate against the projected 24-month runway given the anticipated increase in R&D and SG&A expenses.